好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2005 Annual Meeting | Neuro-oncology Update

Monday 04/11/05
06:45 AM - 08:30 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Breakfast Seminar
Amy A. Pruitt, MD, FAAN
Neuro-oncology
Upon Completion:
Participants should have an overview of the efficacy of the most commonly used chemotherapeutic agents in glial neoplasms and CNS lymphoma; have a detailed overview of ongoing clinical trials to which they can refer patients; and be able to recognize new syndromes from toxicity of new treatment approaches.
No CME available
Advanced
Practitioner, Fellow, Academician, Resident
Event Timeline
06:45 AM - 07:15 AM How Good is Temozolomide?
Josep O. Dalmau, MD, PhD, FAAN
06:45 AM - 08:30 AM Breakfast
07:15 AM - 07:45 AM Beyond Temozolomide: Current Biological Approaches to Primary Brain Tumors
Myrna R. Rosenfeld, MD, PhD, FAAN
07:45 AM - 08:15 AM How Good is Our Therapy for Primary CNS Lymphoma?
Amy A. Pruitt, MD, FAAN
08:15 AM - 08:30 AM Questions and Answers
Faculty Disclosures
Amy A. Pruitt, MD, FAAN Dr. Pruitt has nothing to disclose.
Josep O. Dalmau, MD, PhD, FAAN Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
Myrna R. Rosenfeld, MD, PhD, FAAN Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. An immediate family member of Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Lamson Dugan & Murray LLP. The institution of an immediate family member of Dr. Rosenfeld has received research support from Sage Therapeutics. The institution of an immediate family member of Dr. Rosenfeld has received research support from Edmond J. Safra Foundation. The institution of an immediate family member of Dr. Rosenfeld has received research support from La Caixa Foundation. The institution of an immediate family member of Dr. Rosenfeld has received research support from Spanish Ministry of Health. The institution of an immediate family member of Dr. Rosenfeld has received research support from Department of Health, Government of Catalunya. Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. Dr. Rosenfeld has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Rosenfeld has received publishing royalties from a publication relating to health care. Dr. Rosenfeld has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Rosenfeld has received publishing royalties from a publication relating to health care.